SI
Sofinnova Investments Portfolio holdings
AUM
$1.47B
This Quarter Return
+33.62%
1 Year Return
+17.43%
3 Year Return
+337.79%
5 Year Return
+424.38%
10 Year Return
–
AUM
$1.69B
AUM Growth
+$1.69B
(-5.1%)
Cap. Flow
-$377M
Cap. Flow
% of AUM
-22.25%
Top 10 Holdings %
Top 10 Hldgs %
52.96%
Holding
89
New
27
Increased
18
Reduced
14
Closed
20
Top Buys
| 1 |
Novo Nordisk
NVO
|
$78.6M |
| 2 |
Incyte
INCY
|
$58.7M |
| 3 |
argenx
ARGX
|
$41.2M |
| 4 |
Idexx Laboratories
IDXX
|
$40.6M |
| 5 |
Insulet
PODD
|
$34.5M |
Top Sells
| 1 |
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
|
$437M |
| 2 |
RYZB
RayzeBio, Inc. Common Stock
RYZB
|
$150M |
| 3 |
IMGN
Immunogen Inc
IMGN
|
$45.9M |
| 4 |
Eli Lilly
LLY
|
$37.6M |
| 5 |
Cytokinetics
CYTK
|
$34.6M |
Sector Composition
| 1 | Healthcare | 99.18% |
| 2 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Natera
NTRA
$23.1B
| $142M | 7.9% | 1,550,280 | – | – |
|
2
Vera Therapeutics
VERA
$1.38B
| $120M | 6.71% | 2,793,987 -673,169 | -19% | -$29M |
|
3
Ascendis Pharma
ASND
$11.8B
| $114M | 6.35% | 754,032 | – | – |
|
|
JBIO
4
Jade Biosciences, Inc. Common Stock
JBIO
$258M
| $111M | 6.19% | 3,758,686 | – | – |
|
5
Merck
MRK
$210B
| $85.9M | 4.79% | 651,299 -206,672 | -24% | -$27.3M |
|
|
6
Novo Nordisk
NVO
$251B
| $78.6M | 4.38% | +611,884 | New | +$78.6M |
|
|
7
Incyte
INCY
$16.5B
| $75.6M | 4.21% | 1,327,178 +1,030,609 | +348% | +$58.7M |
|
|
8
argenx
ARGX
$43.6B
| $58.8M | 3.27% | 149,300 +104,579 | +234% | +$41.2M |
|
9
Intuitive Surgical
ISRG
$170B
| $56.2M | 3.13% | 140,880 +13,921 | +11% | +$5.56M |
|
10
Dyne Therapeutics
DYN
$1.92B
| $55M | 3.06% | 1,936,650 +923,145 | +91% | +$26.2M |
|
|
INBX
11
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $45.5M | 2.54% | 1,302,645 +529,688 | +69% | +$18.5M |
|
12
Elanco Animal Health
ELAN
$9.12B
| $41.6M | 2.32% | 2,555,547 +1,361,662 | +114% | +$22.2M |
|
|
13
Idexx Laboratories
IDXX
$51.8B
| $40.6M | 2.26% | +75,224 | New | +$40.6M |
|
14
AstraZeneca
AZN
$248B
| $40.4M | 2.25% | 596,713 -253,864 | -30% | -$17.2M |
|
15
Syndax Pharmaceuticals
SNDX
$1.41B
| $38.3M | 2.13% | 1,608,540 +532,754 | +50% | +$12.7M |
|
|
16
Insulet
PODD
$23.9B
| $37.7M | 2.1% | 220,203 +201,203 | +1,059% | +$34.5M |
|
17
Y-mAbs Therapeutics
YMAB
$388M
| $35.7M | 1.99% | 2,194,278 | – | – |
|
18
IDEAYA Biosciences
IDYA
$2.15B
| $34.3M | 1.91% | 781,596 -677,285 | -46% | -$29.7M |
|
19
Celldex Therapeutics
CLDX
$1.47B
| $33.7M | 1.87% | 801,777 -42,231 | -5% | -$1.77M |
|
|
INZY
20
DELISTED
Inozyme Pharma
INZY
| $32.8M | 1.83% | 4,280,308 | – | – |
|
21
Align Technology
ALGN
$10.3B
| $31.3M | 1.74% | +95,478 | New | +$31.3M |
|
22
ArriVent BioPharma
AVBP
$776M
| $30.3M | 1.69% | +1,696,752 | New | +$30.3M |
|
23
TG Therapeutics
TGTX
$4.65B
| $30.2M | 1.68% | +1,984,962 | New | +$30.2M |
|
24
Sarepta Therapeutics
SRPT
$1.78B
| $29.5M | 1.64% | +227,488 | New | +$29.5M |
|
25
Boston Scientific
BSX
$156B
| $24.2M | 1.35% | 353,851 +222,851 | +170% | +$15.3M |
|